May 11, 2021
Business News

Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer


STAFFORD, Texas–()–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustain peak immunity, as well as to prevent metastatic breast cancer recurrences.

It has been previously reported that the completion of the GP2+GM-CSF Primary…



Click here to view the original article.

Related Posts

You might also like ...

Acorio To Speak on Strategy, Roadmaps, and Insight Data at ServiceNow Knowledge 2021
Vim Wins “Best Overall Health Informatics Solution” in 2021 MedTech Breakthrough Awards Program
Multiple Texas State, Local Governments and Education Institutions Modernize with GTY Technology Solutions for Digital Transformation